Why the study?
ETA receptor blockade reduces blood pressure but promotes sodium retention by an unknown mechanism, leading to the hypothesis that it suppresses pressure natriuresis.
Does selective ETA receptor blockade suppress pressure natriuresis and promote sodium and water retention in rats?
Does selective ETA receptor blockade suppress pressure natriuresis and promote sodium and water retention in rats?
Even highly selective ETA antagonists attenuate pressure natriuresis, providing a mechanistic explanation for the salt and water retention associated with these agents.
Answers are grounded in this paper and cite their sources.
Animal data on ET-1 and pressure natriuresis in salt sensitivity leave open any human mechanistic or therapeutic implications.
Hypertension is a major risk factor for cardiovascular disease. In a significant minority of people, it develops when salt intake is increased (salt-sensitivity). It is not clear whether this represents impaired vascular function or disruption to the relationship between blood pressure (BP) and renal salt-handling (pressure natriuresis, PN). Endothelin-1 (ET-1) regulates BP via ETA and ETB receptor subtypes. Blockade of ETA receptors reduces BP, but promotes sodium retention by an unknown mechanism. ETB blockade increases both BP and sodium retention. We hypothesised that ETA blockade promotes sodium and water retention by suppressing PN. We also investigated whether suppression of PN might reflect off-target ETB blockade. Acute PN was induced by sequential arterial ligation in male Sprague Dawley rats. Intravenous atrasentan (ETA antagonist, 5mg/kg) halved the normal increase in medullary perfusion and reduced sodium and water excretion by >60%. This was not due to off-target ETB blockade because intravenous A-192621 (ETB antagonist, 10mg/kg) increased natriuresis by 50% without modifying medullary perfusion. In a separate experiment in salt-loaded rats monitored by radiotelemetry, oral atrasentan reduced systolic and diastolic BP by ~10mmHg, but additional oral A-192621 reversed these effects. Endogenous ETA stimulation has natriuretic effects mediated by renal vascular dilation while endogenous ETB stimulation in the kidney has antinatriuretic effects via renal tubular mechanisms. Pharmacological manipulation of vascular function with ET antagonists modifies the BP set-point, but even highly selective ETA antagonists attenuate PN, which may be associated with salt and water retention.
No takes yet. Share an insight, caveat, or question.
Culshaw et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: